company background image
RXRX

Recursion Pharmaceuticals NasdaqGS:RXRX Stock Report

Last Price

US$9.34

Market Cap

US$1.8b

7D

0.4%

1Y

-50.4%

Updated

08 Dec, 2022

Data

Company Financials +
RXRX fundamental analysis
Snowflake Score
Valuation3/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

RXRX Stock Overview

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery.

Recursion Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Recursion Pharmaceuticals
Historical stock prices
Current Share PriceUS$9.34
52 Week HighUS$20.21
52 Week LowUS$4.92
Beta0
1 Month Change-2.71%
3 Month Change-29.62%
1 Year Change-50.43%
3 Year Changen/a
5 Year Changen/a
Change since IPO-70.16%

Recent News & Updates

Recent updates

Companies Like Recursion Pharmaceuticals (NASDAQ:RXRX) Can Afford To Invest In Growth

Jul 25
Companies Like Recursion Pharmaceuticals (NASDAQ:RXRX) Can Afford To Invest In Growth

These Analysts Think Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) Sales Are Under Threat

May 16
These Analysts Think Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) Sales Are Under Threat

Recursion Pharmaceuticals, Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

May 14
Recursion Pharmaceuticals, Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Recursion Pharmaceuticals (NASDAQ:RXRX) Is In A Good Position To Deliver On Growth Plans

Apr 07
Recursion Pharmaceuticals (NASDAQ:RXRX) Is In A Good Position To Deliver On Growth Plans

Shareholder Returns

RXRXUS BiotechsUS Market
7D0.4%0.5%-2.8%
1Y-50.4%-8.6%-19.6%

Return vs Industry: RXRX underperformed the US Biotechs industry which returned -11.2% over the past year.

Return vs Market: RXRX underperformed the US Market which returned -21.2% over the past year.

Price Volatility

Is RXRX's price volatile compared to industry and market?
RXRX volatility
RXRX Average Weekly Movement11.9%
Biotechs Industry Average Movement11.1%
Market Average Movement7.4%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market3.3%

Stable Share Price: RXRX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: RXRX's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2013450Chris Gibsonhttps://www.recursion.com

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer.

Recursion Pharmaceuticals, Inc. Fundamentals Summary

How do Recursion Pharmaceuticals's earnings and revenue compare to its market cap?
RXRX fundamental statistics
Market CapUS$1.77b
Earnings (TTM)-US$246.92m
Revenue (TTM)US$28.70m

61.7x

P/S Ratio

-7.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
RXRX income statement (TTM)
RevenueUS$28.70m
Cost of RevenueUS$197.44m
Gross Profit-US$168.74m
Other ExpensesUS$78.17m
Earnings-US$246.92m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.30
Gross Margin-587.95%
Net Profit Margin-860.34%
Debt/Equity Ratio0.2%

How did RXRX perform over the long term?

See historical performance and comparison